急性期精神分裂症患者睡眠与血小板5-HT的关系

目的探讨急性期精神分裂症患者精神症状、睡眠质量与血小板5-HT浓度的关系。方法将符合入组标准的精神分裂症患者68例按入院的先后顺序分为喹硫平组34例和阿立哌哇组34例,用高效液相色谱仪（HPLC—ECD）在治疗前后测定血小板5-HT浓度,用匹兹堡睡眠质量指数（PSQI）和睡眠状况自评量表（SRSS）进行主观睡眠评价,用阳性和阴性症状量表（PANSS）、简明精神病评定量表（BPRS）评定精神症状。正常对照组30例。结果患者组治疗前5-HT浓度与对照组比较,差异无统计学意义（P〉0．05）,对照组、患者组治疗前后血小板5-HT浓度性别比较差异无统计学意义（P〉0．05）。多元逐步回归分析显示,患者组治疗前5-HT浓度与PSQI总分呈正相关（r=0．328,P=0．013）;治疗后5-HT浓度与病程、家族史、首次发病年龄呈正相关（r=0．422,P=0．001;r=0．522,P=0.000;r=0．575,P=0.000）;5-HT浓度变化率与治疗前PSQI因子分--日间功能、入睡时间及家族史、治疗前SRSS总分呈正相关（r=0．429,P=0．001;r=0．644,P=0．000;r=0．539,P=0．000;r=0．694,P=0．000）。结论血小板5-HT浓度在一定程度反映了中枢5-HT的功能,以血小板5-HT含量作为精神分裂症的生物学标记还有待于进一步探讨。     

综合性心理干预对抑郁症患者亲属心理健康的影响

目的探讨综合性心理干预对抑郁症患者亲属心理健康状况的影响。方法对抑郁症患者亲属进行为期8周的心理干预,在干预前后采用SCL-90、SAS、SDS对亲属实施测评。结果抑郁症患者亲属的SCL-90各因子中抑郁、焦虑、躯体化、恐怖因子以及SAS、SDS评分高于全国常模（t=1．47—7．96,P〈0．05）,干预后SCL-90各因子中抑郁、焦虑、躯体化、恐怖因子、SAS、SDS评分较干预前显著降低（t=2．31-4．69,P〈0．05）。结论抑郁症患者亲属的心理问题较为明显,而综合性心理干预可有效改善亲属的心理状况,提高其生活质量。     

躯体化障碍与以躯体症状为主诉的抑郁症个性、躯体主诉、生活质量比较

目的探讨躯体化障碍与以躯体症状为主诉的抑郁症患者个性、躯体主诉、生活质量差异。方法对30例躯体化障碍和30例以躯体症状为主诉的抑郁症患者分别采用自编躯体症状主诉频数表,艾森克人格问卷（EPQ）、汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）、健康状况调查问卷（SF-36）等进行评定,对影响生活质量的某些因素进行多元回归分析。结果两组躯体主诉无显著性差异（P〉0．0．5）;躯体化障碍组E分显著低于抑郁症组,N分显著高于抑郁症组（P〈0．05）;两组HAMD总分无差异（P〉0．05）,躯体化障碍组焦虑／躯体化及认知障碍因子分显著高于抑郁症（P〈0．05）,躯体化障碍的HAMA总分及躯体性焦虑分显著高于抑郁症组（P〈0．05）;躯体化障碍组生理机能、生理职能、躯体疼痛分量表评分均显著低于抑郁症组（P〈0．05）;多元回归分析结果,影响两组患者生活质量的主要因素依次为HAMD总分、HAMA总分、EPQ精神质因子、病程。结论躯体化障碍与以躯体症状为主诉的抑郁症患者在个性、HAMA总分、躯体焦虑因子分、生活质量方面有差异,两者的个性、疾病严重程度、病程为影响生活质量的重要因素。     

利培酮辅助治疗难治性抑郁症对患者血小板5-羟色胺浓度的影响

目的探索小剂量利培酮合并抗抑郁剂对难治性抑郁症患者血小板5-羟色胺(5-HT)浓度的影响。方法38例难治性抑郁症患者在合并利培酮治疗前及治疗后4周末分别检测患者外周血血小板5-HT浓度,并评估汉密顿抑郁量表17项(HAMD17)、汉密顿焦虑量表(HAMA)。结果在合并利培酮治疗后血小板5-HT浓度减低,与合并治疗前相比,接近显著变化水平(P=0.05),治疗后HAMD、HAMA总分及各因子分与治疗前相比有显著差异(P<0.05);合并利培酮治疗后患者血小板5-HT浓度与本次病程、HAMD阻滞因子分、HAMA总分与精神焦虑因子分呈正相关,与HAMD总分减分值及睡眠因子减分值呈负相关;治疗前后5-HT浓度差值与发作次数负相关,与HAMD阻滞因子减分值正相关。结论小剂量利培酮合并抗抑郁剂对难治性抑郁症患者治疗4周症状有改善,同时可能引起患者血小板5-HT浓度减低;血小板内5-HT浓度与焦虑症状、阻滞等症状可能相关;血小板5-HT浓度降低与患者的阻滞症状改善可能存在一定的关系。     

5-羟色胺和胆固醇水平对抑郁症患者再次自杀风险评估的研究

目的 探讨抑郁症患者血小板5-羟色胺（5-HT）和胆固醇水平与抑郁症患者再次自杀的关系.方法 对33例有自杀行为的抑郁症患者在接受治疗前测定血小板5-HT和胆固醇水平,评定汉密尔顿抑郁量表（HAMD-24）和Beck绝望量表（BHS）,然后进行2年的随访.结果 16例患者再次出现自杀行为,再次自杀组血小板5-HT及血清胆固醇水平显著低于无再次自杀组（P＜0.01）.5-HT和血清胆固醇水平与HAMD-24、BHS分及自杀次数、自杀严重程度均呈负相关（P＜0.01）,且5-HT与血清胆固醇水平呈正相关（P＜0.01）.多重回归分析显示血小板5-HT浓度、家族史是自杀次数的主要影响因素.结论 低血小板5-HT及血清胆固醇浓度是抑郁症自杀的危险因素,对抑郁症自杀行为可能具有一定的的预测作用.     

躯体化症状为主的抑郁症心率变异性对照研究

目的：探讨躯体化症状为主的抑郁症患者自主神经系统的特点及抑郁症躯体化表现的发生机制。方法：对30例躯体化症状为主的患者（A组）和30例情绪症状为主的患者（B组）及30例健康正常者（C组）分别进行汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评定及短时（10min）心率变异性（HRV）分析。结果：A、B、C3组HRV分析指标RR间期标准差（SDNN）分别为（50.84±19.92）ms、（94.93±28.80）ms、（105.77±22.05）ms,A组显著低于C组（t=5.68,P〈0.01）,较B组低（t=3.73,P〈0.05）;3组LF/HF分别为（6.26±2.11）ms、（3.51±2.44）ms、（1.80±1.07）ms,A组显著高于C组（t=6.35,P〈0.01）,较B组高（t=2.50,P〈0.05）;A组HAMD评分（28.30±6.26）分高于B组（24.35±6.69）分,二者差异有显著性（t=3.14,P〈0.05）;A组HAMA评分（22.70±4.92）分显著高于B组（13.05±4.71）分,二者差异有显著性（t=6.17,P〈0.01）;HAMD焦虑/躯体化因子分与HRV指标SDNN、LF、HF、VLF和LF/HF均呈中度相关（r分别为0.49、0.61、0.58、0.50、0.63）（P〈0.05或P〈0.01）。结论：躯体化症状表现为主的抑郁症患者多伴有焦虑,自主神经功能紊乱。     

高频重复经颅磁刺激对老年抑郁症伴轻度认知功能损害患者的疗效

目的探讨高频重复经颅磁刺激（rTMs）对伴有轻度认知功能损害的老年抑郁症患者的疗效。方法将48例伴有轻度认知损害的老年抑郁症患者随机分为对照组和试验组。对试验组患者进行为期4周、频率为20Hz的rTMS治疗。在治疗前、治疗后和治疗后3个月分别进行汉密尔顿抑郁量表（HAMD）、简易精神状态量表（MMSE）,事件相关电位P300测试。结果治疗后,试验组HAMD评分低于对照组（t=-3．711,P=0．001）,3个月后差异仍有统计学意义（t=-3．978,P〈0．01）。治疗后,试验组的MMSE评分高于对照组（t=2．705,P=0．010）,3个月后差异仍有统计学意义t=2．934,P=0．006）。治疗后和治疗3个月后,和对照组相比,试验组Fz和Cz的P300波幅较大,差异有统计学意义（P〈0．01）。治疗后和治疗3个月后,试验组Fz和Cz的P300潜伏期短于对照组,差异均有统计学意义（P〈0．05）。结论rTMS治疗可同时改善伴轻度认知损害老年抑郁症患者的抑郁情绪和认知功能。     

舍曲林合并奥氮平治疗躯体形式障碍的临床对照研究

目的观察舍曲林合并奥氮平治疗躯体形式障碍的临床疗效特点。方法将符合入组标准的75例患者随机分为舍曲林合并奥氮平组（研究组）与舍曲林组（对照组），均进行6周系统治疗和观察，分别于治疗前、治疗后第1、2、4、6周末采用汉密顿抑郁量表（HAMD）总评分及其焦虑／躯体化因子和睡眠因子评分加以评定疗效。结果两组HAMD总分在疗后第1、2、6周末有显著性差异（P〈0．05），在疗后第4周末有极显著差异（P〈0.01）；在HAMD因子方面，两组焦虑／躯体化评分在疗后第1、2周末有极显著差异（P〈0．01），在疗后第4周末有显著差异（P〈0．05）；睡眠障碍评分在疗后第1、2、4周末有极显著差异（P〈0．01），在第6周末有显著差异（p〈0．05）。两组显效率在疗后第1、2、4周末有极显著性差异（P〈0．01），在疗后第6周末有显著差异（P〈0．05）。两组患者总体副反应发生率无显著性差异（P〉0．05）。结论舍曲林合并小剂量奥氮平治疗躯体形式障碍不仅起效较快，能迅速改善睡眠及焦虑／躯体化症状，而且明显提高疗效和患者的治疗依从性，却又并不明显增加药物副反应，因此推荐该方法临床试用。     

脑梗死患者血浆氧化低密度脂蛋白与一氧化氮、假性血友病因子及血浆颗粒膜蛋白的关系研究

目的探讨动脉粥样硬化性脑梗死患者血浆氧化低密度脂蛋白与血管内皮损伤及血小板活化程度的关系。方法用酶联免疫吸附测定（ELISA）的方法检测49例脑梗死患者和50例相匹配的对照组血浆氧化低密度脂蛋白（OX-LDL）、血管性假血友病因子（VWF）、血浆颗粒膜蛋白（GMP-140）水平，同时用硝酸还原酶比色法测定血清一氧化氮（NO）水平，并把、VWF、GMP-140、NO与OX-LDL作相关分析。结果脑梗死组血浆OX-LDL、、VWF、GMP-140明显高于对照组（t=2．91，P〈0．01；t=3．94，P〈0．001；t=2．08，P〈0．05），而脑梗死组血清NO水平明显低于对照组（t=4．02，P〈0．001）；相关分析表明血浆OX-LDL水平与血清NO水平呈负相关（r=-0．204，P〈0．05），与血浆懈呈正相关（r=0．60，P〈0．01），与血浆GMP-140呈正相关（r=0．430，P〈0．01）。结论脑梗死患者的血浆OX-LDL明显增高，而OX-LDL增高可能是脑梗死的危险因素。     

脑脊液5-羟色胺和多巴胺及其代谢产物在病毒性脑炎和精神分裂症鉴别诊断中的价值

目的探讨脑脊液5-羟色胺（5-HT）、多巴胺（DA）及其代谢产物水平在病毒性脑炎和精神分裂症鉴别诊断中的价值。方法对病毒性脑炎和脑膜脑炎患者（简称病脑组）67例、精神分裂症患者37例和病例对照患者21例采用高效液相色谱法（HPLC）检测其脑脊液中5-HT、DA、5-羟吲哚乙酸（5-HIAA）和高香草酸（HVA）水平,并进行比较。结果（1）病脑组5-HT、5-HIAA、5-HIAA／HVA和5-HT／DA均明显低于病例对照组（P〈0．05～0．01）,而HVA则明显高于病例对照组（P〈0．01）;病脑组脑脊液中5-HIAA、5-HIAA／5．HT和5-H｜AA／HVA日月显低于精神分裂症组（均P〈0．01）,而HVA／DA则高于精神分裂症组（P〈0．05）;精神分裂症组脑脊液中5-HIAA／5-HT高于病例对照组（P〈0．05）,5-HT／DA低于病例对照组（P〈0．05）。（2）病脑组有精神症状者脑脊液中5-HIAA浓度低于无精神症状者（P〈0．05）,5-HT、5．HIAA、5-HIAA／5．HT和5-HIAA／HVA均低于精神分裂症组（P〈0．05～0．01）,而HVA／DA高于精神分裂症组（P〈0．05）。结论病毒性脑炎患者脑脊液中可能存在5-HT和DA系统失衡;脑脊液中5-HT、DA及其代谢产物的水平可能有助于病毒性脑炎和精神分裂症的鉴别诊断。     

四磨汤口服液联合西酞普兰治疗伴焦虑抑郁的腹泻型肠易激综合征患者的疗效观察

目的 探讨四磨汤口服液联合西酞普兰治疗伴焦虑抑郁的腹泻型肠易激综合征(IBS)患者的临床疗效及对血清5-羟色胺(5-HT)、去甲肾上腺素(NE)、髓过氧化物酶(MPO)的影响.方法 选取我院2017年1月～2019年6月期间收治的118例伴焦虑抑郁的腹泻型IBS患者作为研究对象,采用随机数字表分为对照组和观察组,每组各...     

自杀行为患者血小板5-HT浓度

目的 通过测定伴自杀行为的精神病患者血小板5-HT浓度,以探讨其5-HT功能与自杀行为的关系。方法 研究组65例(男21例,女44例);疾病对照组60例(男25例,女35例)。采用HAMD及PANSS评定证状。在治疗前及治疗后6周检测血小板5-HT浓度,采用HPLC及电化学检测仪测定浓度。结果 治疗前两组血小板5-HT浓度的差异无统计意义,治疗后两组差异有统计学意义(P为0.012)。自杀1次与自杀至少2次者之间治疗前血小板5-HT的差异有统计学意义(P为0.035)。治疗后HAMD及PANSS评分的变化与血小板5-HT浓度变化之间无显著相关性。结论 精神疾病伴自杀行为者血小板5-HT浓度未见显著下降。自杀至少2次者的浓度明显降低,提示与1次自杀者之间存在异质性。精神症状的变化与血小板5-HT浓度的变化之间无显著相关性。     

Depressed patients have higher body temperature: 5-HT transporter long promoter region effects

BACKGROUND: Depression has been associated with a decrease in intracellular serotonin (5-HT) reuptake through its transporter, SERT. The 5-HT transporter long promoter region (5-HTTLPR) deletion in the SERT gene has also been associated with a decrease in 5-HT reuptake. Conversely, increases in extracellular 5-HT have been associated with increased temperature. It has not been established, however, whether body temperature in depressed patients is different from controls. Here, we hypothesized that temperature would be increased in depressed patients as well as in those with the 5-HTTLPR deletion. METHODS: A strict oral temperature protocol employed single, cross-sectional, naturalistic time-of-day temperature measures in 125 subjects (46 normal controls, 79 outpatients with major depression). Controls and depressed patients were free of psychotropic medication and classified by the Structured Clinical Interview for Psychiatric Diagnoses. Eighty-one of the subjects (68 depressed, 13 normal) were additionally genotyped for 5-HTTLPR polymorphisms. RESULTS: Depressed patients had a significantly higher uncorrected body temperature (mean +/- SD 98.38 +/- 0.61 degrees F) than controls (mean +/- SD 98.13 +/- 0.59 degrees F; F = 4.8, p = 0.03). An age (F = 14.09, p < 0.001) and time-of-day (11.4, p = 0.001) correction revealed a more robust (F = 14.02, p < 0.001) difference between depressed patients (mean +/- SD 98.44 +/- 0.55 degrees F) and controls (mean +/- SD 98.02 +/- 0.56 degrees F). When normalized for age and circadian differences between subjects, random, outpatient oral temperatures had a sensitivity of 63% and a specificity of 76% in identifying the depressed subjects from the controls. Independent of depression, subjects with the 5-HTTLPR deletion (short SERT allele) were warmer (mean +/- SD 98.33 +/- 0.65 degrees F) than those lacking the short allele on either chromosome (mean +/- SD 97.91 +/- 0.69 degrees F; F = 7.0, p = 0.01). However, the genotype did not explain the temperature differences between controls and depressed patients. CONCLUSION: This is the first demonstration of an increased daytime body temperature in cases with major depression. Subjects with a corrected temperature above 98.3 degrees F were 2.6-fold more likely to be depressed. The results may strengthen the hypothesis of an inflammatory component of depression. In addition, the findings suggest a potential link between genetic differences in 5-HT transport and body temperature.     

抑郁症患者治疗前后性激素水平的变化及与临床特征的关系

目的　探讨抑郁症患者治疗前后性激素水平的变化及其与临床特征的关系。方法　用酶联免疫吸附法测定 30例抑郁症患者治疗前、后血清雌二醇、孕酮、睾酮水平 ,并与 30名正常对照比较 ,同时作相关分析。结果　男性和女性抑郁症患者血清雌二醇水平均显著低于正常对照 (t=- 4 2 4 5 ,P <0 0 1;t =- 4 342 ,P <0 0 1) ,雌二醇水平与HAMD分和HAMA分呈负相关 (r =- 0 5 0 4 ,P <0 0 1;r =- 0 389,P <0 0 5 )。男性患者的睾酮水平显著低于正常对照 (t=- 2 319,P <0 0 5 ) ,而女性患者的睾酮水平与正常对照无显著差异 (t=0 5 6 9,P >0 0 5 )。抑郁症患者的孕酮水平无显著变化 (P >0 0 5 )。帕罗西汀治疗后 ,雌二醇水平显著升高 (t =- 4 335 ,P <0 0 1;t =- 4 0 14 ,P <0 0 1) ,但仍低于正常对照 (t=- 2 4 99,P <0 0 5 ;t=- 2 4 4 6 ,P <0 0 5 ) ,男性患者的睾酮水平恢复正常 ,孕酮水平及女性患者的睾酮水平治疗前后无显著变化 (P >0 0 5 )。治疗有效者比疗效不佳者的雌二醇水平显著增高 (t=4 12 7,P <0 0 1)。结论　抑郁症患者存在性激素水平改变 ,治疗后性激素水平仍未完全恢复正常 ,患者病前雌二醇水平与HAMD和HAMA分呈负相关 ,与抗抑郁疗效呈正相关。     

抑郁症患者治疗前后血清脑源性神经营养因子水平变化及相关因素分析

目的 探讨抑郁症患者血清脑源性神经营养因子(BDNF)水平及其变化与负性生活事件、抑郁症发病及治疗效应的关系.方法 采用横断面的病例-对照及前瞻性自身对照设计.对所有抑郁症患者给予抗抑郁治疗(包括抗抑郁药和改良电抽搐治疗),并随访治疗8周;采用酶联免疫吸附法测定63例抑郁症患者(抑郁症组)治疗前和治疗第2,4,8周末及80名正常对照(以下简称对照组)血清BDNF水平,并评定汉密尔顿抑郁量表(HAMD)和生活事件量表.结果 抑郁症组治疗前血清BDNF水平[(24±14)μg/L]显著低于对照组[(36±15)μg/L](t=-4.863,P=0.000),并与病前1年负性生活事件刺激值、治疗前HAMD总分均显著负相关(r=-0.331,P=0.008;r=-0.343,P=0.006),而后两者有相互正相关(r=0.292,P=0.020);治疗第2周末血清BDNF水平仍显著低于对照绢(t=-5.990,P=0.000),并与其抑郁症状严重度平行负相关(r=-0.269,P=0.033),且其血清BDNF增加率与HAMD减分率平行正相关(r=0.252,P=0.047);治疗第4,8周末血清BDNF水平均显著高于治疗前(经ISD检验,P=0.000;P=0.005),与对照组的差异均无统计学意义(P均＞0.05).治疗第2,4,8周末HAMD总分渐减并均低于治疗前(P均=0.001),且其HAMD平均减分率渐升(分别为40%,66%和74%).结论血清BDNF低下与负性生活事件、抑郁症发病密切相关,血清BDNF升高可能为抗抑郁治疗临床疗效的重要指标之一.     

Platelet serotonin concentration and suicidal behavior in combat related posttraumatic stress disorder

Posttraumatic stress disorder (PTSD) is a serious and global problem, a psychiatric disorder that frequently occurs with different comorbidities, and is associated with a high suicide rate. Pathophysiologically, both PTSD and suicidal behavior are related to disturbances in the central serotonergic system. Serotonin (5-hydroxytryptamine, 5-HT) controls emotional behavior, anxiety, impulsivity and aggression, and nearly all known antidepressants and antianxiety drugs affect 5-HT transmission. Platelet 5-HT can be used as a limited peripheral marker of the central serotonergic synaptosomes, since it is related to particular basic psychopathological characteristics of several psychiatric disorders. Platelet 5-HT concentration has been reported to be similar in PTSD subjects and healthy controls, but suicidal patients across different psychiatric diagnoses have reduced platelet 5-HT concentration. This study examined platelet 5-HT concentration by the spectrofluorimetric method in male subjects: 73 suicidal and 47 non-suicidal veterans with current and chronic combat related PTSD, 45 suicidal and 30 non-suicidal comparative non-PTSD subjects and 147 healthy men. The presence of suicidal behavior (score=0, non-suicidal; scores > or =1, suicidal) was assessed with the Hamilton Depression Rating Scale-17 (HDRS). Platelet 5-HT concentration was significantly lower in suicidal PTSD and non-PTSD patients compared to non-suicidal patients or healthy controls. Since the majority of patients scored very low on item 3 of HDRS, no significant correlation between suicidal scores and platelet 5-HT concentration was found. These results show that reduced platelet 5-HT concentration is related to suicidal behavior in PTSD, and suggest that platelet 5-HT concentration might be used as a peripheral marker to predict suicidal behavior across psychiatric diagnoses.     

生物反馈治疗卒中后焦虑抑郁状态伴失眠的研究

目的 研究生物反馈治疗卒中恢复期焦虑抑郁状态伴失眠的疗效及安全性。 方法 纳入卒中恢复期焦虑抑郁伴失眠患者,均给予生物反馈训练,训练方法为每周五次,每次 30 min的自主神经系统放松康复训练。所有患者在训练前后评定汉密尔顿焦虑量表（Hamilton Anxiety Scale,HAMA）、汉密尔顿抑郁量表（Hamilton Depression Scale,HAMD）、匹兹堡睡眠质量指数量表 （Pittsburgh Sleep Quality Index,PSQI）、患者健康问卷-9（Patient Health Questionnaire-9,PHQ-9）、简 易精神状态检查表（Mi ni -mental State Examination,MMSE）、Fugle-Meyer肢体功能评分（Fugl e-Meyer Scale,FMS）、美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale,NIHSS）以及 Barthel指数（Barthel Index,BI）,并采集患者的睡眠时间,对比分析训练前后这些量表评分及睡眠时 间的变化。 结果 研究共纳入并完成3 0例患者的数据统计。治疗后患者睡眠时间较治疗前显著增 加[（4.81±1.58）h vs（7.30±1.34）h,P＜0.001]。HA M A[（17.50±8.41）vs（9.00±7.01）]和 HAMD（[ 19.53±7.82）vs（9.23±4.42）]评分均有显著改善（均P＜0.001）。训练4周后患者的MMSE评 分有提高,Fugl e-Meyer分数增加,Barthel指数增加,但无统计学意义,NIHSS评分降低,差异有显著性 （P =0.033）。 结论 生物反馈疗法有利于卒中后焦虑抑郁伴失眠患者的睡眠和情绪改善,提高康复效果。     

焦虑和抑郁障碍共病血浆单胺类神经递质研究

目的：探讨血浆单胺类神经递质与焦虑和抑郁障碍共病的关系。方法：使用高效液相－电化学检测法检测25例焦虑和抑郁障碍共病、30例抑郁症、20例焦虑症患者和21例正常人的血浆去甲肾上腺素（NE）和5－羟色胺（5－HT）浓度。结果：3组患者的血浆NE浓度均显著高于正常对照组,但共病组与抑郁症组和焦虑症组无明显差异;抑郁症组的血浆5－HT浓度显著低于正常对照组,共病组和焦虑症组的血浆5－HT浓度与正常对照组无显著差异,3组患者之间血浆5－HT浓度也无显著差异。结论：血浆单胺类神经递质不能鉴别抑郁症和焦虑症,也不支持焦虑和抑郁障碍共病是第3种疾病的观点。     

Platelet serotonin functions in untreated major depression

The uptake of [14C]5-HT, [3H]paroxetine and [3H]LSD binding was determined in platelets from 30 untreated patients with major depression and compared with corresponding variables from 30 healthy age-, sex- and season-matched control subjects. The maximum velocity (Vmax) for the 5-HT uptake was significantly decreased in patients (P = 0.014) compared to control subjects. Depressed women had significantly lower Vmax than female control subjects. In men, Vmax did not differ between patients and control subjects. Vmax was significantly lower in male inpatients compared with male outpatients (P = 0.05). The density (Bmax) of 5-HT uptake sites was found to be significantly increased in patients (P < 0.05) compared to control subjects and male patients had significantly higher Bmax than male control subjects, but there was no difference between female control subjects and female patients. No significant difference was found in Bmax of 5-HT2-receptors between patients and control subjects. A positive correlation was found between Bmax of 5-HT2-uptake sites and the degree of anxiety and between Bmax of 5-HT2 receptors and MADRS scores. Bmax of 5-HT2-receptors was positively correlated with the degree of suicidality. The results in the present study indicate that there may be a gender difference in serotonergic dysfunction in depression.     

Increased P wave duration in patients with depression or anxiety disorder

BACKGROUND:Activation of the sympathetic nervous system plays an important role in regulating cardiovascular actions. P wave parameters can provide general information on central cardiovascular autonomic regulatory responses, which are altered in patients with anxiety disorders and depression. In particular, there are no reports addressing changes in P wave duration and dispersion.OBJECTIVE:To compare the differences in P wave duration and P wave dispersion between patients with anxiety disorders and depression, because patients with anxiety disorders and depression develop abnormal electrocardiograms.PARTICIPANTS:A total of 71 consecutive patients with depression and anxiety disorders, as well as 50 physically and mentally healthy age- and gender-matched controls were selected.METHODS:Electrocardiogram records were obtained at the time of admission to the outpatient clinics.MAIN OUTCOME MEASURES:P wave duration and P wave dispersion were measured.RESULTS:Both the maximum (Pmax) and minimum (Pmin) P wave duration were greater in patients with psychiatric disorders than in healthy controls. Pmax was significantly greater in patients with depression or anxiety disorders (Bonferroni test, P < 0.017). The P wave dispersion was similar between patients and controls (P > 0.017). P waves were similar between panic patients and other anxiety patients. Beck depression results were positively correlated with Pmin and Pmax (r = 0.374, 0.302, P = 0.013, 0.049, respectively), and not associated with P wave dispersion (P > 0.05).CONCLUSION:Psychiatric disorders are associated with increases in Pmax, but not with P wave dispersion. The P wave changes were associated with the degree of depression.